These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 34663326)

  • 61. BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection: A Preliminary Report.
    Bianchi FP; Germinario CA; Migliore G; Vimercati L; Martinelli A; Lobifaro A; Tafuri S; Stefanizzi P;
    J Infect Dis; 2021 Aug; 224(3):431-434. PubMed ID: 34007998
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile.
    Jara A; Undurraga EA; González C; Paredes F; Fontecilla T; Jara G; Pizarro A; Acevedo J; Leo K; Leon F; Sans C; Leighton P; Suárez P; García-Escorza H; Araos R
    N Engl J Med; 2021 Sep; 385(10):875-884. PubMed ID: 34233097
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study.
    Ranzani OT; Hitchings MDT; Dorion M; D'Agostini TL; de Paula RC; de Paula OFP; Villela EFM; Torres MSS; de Oliveira SB; Schulz W; Almiron M; Said R; de Oliveira RD; Vieira da Silva P; de Araújo WN; Gorinchteyn JC; Andrews JR; Cummings DAT; Ko AI; Croda J
    BMJ; 2021 Aug; 374():n2015. PubMed ID: 34417194
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study.
    Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos C; Lucas C; Macario F; Haase M
    J Nephrol; 2021 Aug; 34(4):975-983. PubMed ID: 34050904
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Infection control, occupational and public health measures including mRNA-based vaccination against SARS-CoV-2 infections to protect healthcare workers from variants of concern: A 14-month observational study using surveillance data.
    Yassi A; Grant JM; Lockhart K; Barker S; Sprague S; Okpani AI; Wong T; Daly P; Henderson W; Lubin S; Kim Sing C
    PLoS One; 2021; 16(7):e0254920. PubMed ID: 34270608
    [TBL] [Abstract][Full Text] [Related]  

  • 66. An assessment of the vaccination of school-aged children in England against SARS-CoV-2.
    Keeling MJ; Moore SE
    BMC Med; 2022 May; 20(1):196. PubMed ID: 35581585
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study.
    Urakawa R; Isomura ET; Matsunaga K; Kubota K; Ike M
    BMC Infect Dis; 2022 Feb; 22(1):179. PubMed ID: 35197017
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Development of thrombocytopenic purpura following BNT162b2 mRNA COVID-19 vaccination].
    Shibata K; Tanaka H; Otani A; Kubo M; Hasegawa A; Amano I
    Rinsho Ketsueki; 2021; 62(10):1519-1521. PubMed ID: 34732627
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.
    Mevorach D; Anis E; Cedar N; Bromberg M; Haas EJ; Nadir E; Olsha-Castell S; Arad D; Hasin T; Levi N; Asleh R; Amir O; Meir K; Cohen D; Dichtiar R; Novick D; Hershkovitz Y; Dagan R; Leitersdorf I; Ben-Ami R; Miskin I; Saliba W; Muhsen K; Levi Y; Green MS; Keinan-Boker L; Alroy-Preis S
    N Engl J Med; 2021 Dec; 385(23):2140-2149. PubMed ID: 34614328
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Development of autoimmune hemolytic anemia after BNT162b2 mRNA COVID-19 vaccination].
    Okuno S; Hashimoto K; Shimizu R; Takagi E; Kajiguchi T
    Rinsho Ketsueki; 2021; 62(10):1510-1514. PubMed ID: 34732625
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals.
    Kustin T; Harel N; Finkel U; Perchik S; Harari S; Tahor M; Caspi I; Levy R; Leshchinsky M; Ken Dror S; Bergerzon G; Gadban H; Gadban F; Eliassian E; Shimron O; Saleh L; Ben-Zvi H; Keren Taraday E; Amichay D; Ben-Dor A; Sagas D; Strauss M; Shemer Avni Y; Huppert A; Kepten E; Balicer RD; Netzer D; Ben-Shachar S; Stern A
    Nat Med; 2021 Aug; 27(8):1379-1384. PubMed ID: 34127854
    [TBL] [Abstract][Full Text] [Related]  

  • 72. First Dose of BNT162b2 mRNA Vaccine in a Healthcare Worker Cohort Is Associated With Reduced Symptomatic and Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
    Lillie PJ; O'Brien P; Lawtie M; Jessop S; Easom NJW; Patmore R
    Clin Infect Dis; 2021 Nov; 73(10):1906-1908. PubMed ID: 33893480
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Characteristics associated with COVID-19 vaccine uptake among adults aged 50 years and above in England (8 December 2020-17 May 2021): a population-level observational study.
    Tessier E; Rai Y; Clarke E; Lakhani A; Tsang C; Makwana A; Heard H; Rickeard T; Lakhani S; Roy P; Edelstein M; Ramsay M; Lopez-Bernal J; White J; Andrews N; Campbell CNJ; Stowe J
    BMJ Open; 2022 Mar; 12(3):e055278. PubMed ID: 35232787
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data.
    Glatman-Freedman A; Bromberg M; Dichtiar R; Hershkovitz Y; Keinan-Boker L
    EBioMedicine; 2021 Oct; 72():103574. PubMed ID: 34537449
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of Influenza Vaccination on the Response to BNT162b2 Messenger RNA COVID-19 Vaccine in Healthcare Workers.
    Greco M; Cucci F; Portulano P; Lazzari RA; Caldararo C; Sicuro F; Catanese C; Lobreglio G
    J Clin Med Res; 2021 Dec; 13(12):549-555. PubMed ID: 35059073
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies.
    Chang S; Liu H; Wu J; Xiao W; Chen S; Qiu S; Duan G; Song H; Zhang R
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335101
    [TBL] [Abstract][Full Text] [Related]  

  • 77. COVID-19 Vaccination and Asymptomatic Infection: Effect of BNT162b2 mRNA Vaccine on the Incidence of COVID-19 and Duration of Sick Leave Among Healthcare Workers.
    Prato' S; Paladino ME; Riva MA; Belingheri M
    J Occup Environ Med; 2021 Dec; 63(12):e868-e870. PubMed ID: 34538839
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2.
    Di Fusco M; Moran MM; Cane A; Curcio D; Khan F; Malhotra D; Surinach A; Miles A; Swerdlow D; McLaughlin JM; Nguyen JL
    J Med Econ; 2021; 24(1):1248-1260. PubMed ID: 34844493
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Active Covid-19 infection and transmission after the first dose of the BNT162b2 mRNA vaccination in Saudi Arabia: A case report.
    Allam AA; Sayed AA
    J Infect Public Health; 2021 Aug; 14(8):1123-1125. PubMed ID: 34303125
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England.
    Powell AA; Power L; Westrop S; McOwat K; Campbell H; Simmons R; Ramsay ME; Brown K; Ladhani SN; Amirthalingam G
    Euro Surveill; 2021 Jul; 26(28):. PubMed ID: 34269172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.